tranexamic acid and Absence Seizure
tranexamic acid has been researched along with Absence Seizure in 74 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Tranexamic acid (TXA) reduces surgical bleeding and reduces death from bleeding after trauma and childbirth." | 9.12 | Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. ( Murao, S; Nakata, H; Roberts, I; Yamakawa, K, 2021) |
"This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 9.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
"The aim of this meta-analysis was to assess whether tranexamic acid (TXA) therapy for adult cardiac surgery is associated with an increase in the risk of seizures, and we performed a meta-analysis of randomized controlled trials (RCTs) and non-randomized observational studies." | 8.95 | Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies. ( Ando, T; Takagi, H; Umemoto, T, 2017) |
"To investigate the incidence rate of tranexamic acid (TXA)-associated seizures." | 8.93 | Tranexamic acid-associated seizures: A meta-analysis. ( Lin, Z; Xiaoyi, Z, 2016) |
" The most commonly used antifibrinolytic drug, tranexamic acid, is associated with an increased incidence of postoperative seizures." | 8.93 | Tranexamic acid-associated seizures: Causes and treatment. ( Avramescu, S; Lecker, I; Mazer, CD; Orser, BA; Wang, DS; Whissell, PD, 2016) |
"This study described the outcomes of patients receiving topical, nebulized, endobronchial, or systemic tranexamic acid (TXA) for bleeding events while on extracorporeal membrane oxygenation (ECMO)." | 8.31 | Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation. ( Jakowenko, ND; Kalvelage, EL; Macielak, RJ; Nabzdyk, CGS; Nei, SD; Seelhammer, TG; Wieruszewski, PM, 2023) |
"To evaluate the effects of administering tranexamic acid (TXA) after cardiopulmonary bypass, instead of after anesthesia induction, on postoperative seizures and blood transfusion requirements." | 8.12 | Tranexamic acid after cardiopulmonary bypass does not increase risk of postoperative seizures: a retrospective study. ( Chen, C; Du, L; Liu, J, 2022) |
"In cardiac surgery, use of the antifibrinolytic agent tranexamic acid (TXA) and acute perioperative stroke are both associated with convulsive seizures." | 8.02 | Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery. ( Deutsch, MA; Gummert, JF; Hulde, N; Koster, A; von Dossow, V; Zittermann, A, 2021) |
"High-dose tranexamic acid (TXA) can cause seizures in patients who have undergone pulmonary endarterectomy (PTE)." | 7.96 | Deprescribing practices for anticonvulsants after benign seizures secondary to high-dose tranexamic acid in a single, large UK cardiothoracic centre. ( Barrow, L; Jenkins, D; Ng, CY; Tan, Z; Valchanov, K, 2020) |
"The incidence of postoperative nonischemic seizures associated with the use of tranexamic acid (TXA) and the possibility of prevention with a low-dose regimen of TXA were evaluated." | 7.85 | Low-Dose Versus High-Dose Tranexamic Acid Reduces the Risk of Nonischemic Seizures After Cardiac Surgery With Cardiopulmonary Bypass. ( Ayoub, C; Chamberland, MÈ; Cogan, J; Couture, P; Denault, A; Deschamps, A; Desjardins, G; Laliberté, É; Lebon, JS; Rochon, A, 2017) |
"Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding." | 7.83 | Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024) |
"To investigate the incidence of postoperative generalized seizures in patients undergoing aortic valve replacement (AVR) under extracorporeal circulation, who received either high-dose tranexamic acid (TXA) or epsilon aminocaproic acid (EACA) as an antifibrinolytic agent." | 7.77 | High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. ( Beyersdorf, F; Keyl, C; Lehane, C; Stampf, S; Trenk, D; Uhl, R; Wiesenack, C, 2011) |
"A 68-year-old man was admitted and received tranexamic acid for persistent hemoptysis." | 7.77 | Generalized convulsion resulted in hyperammonemia during treatment with tranexamic acid for hemoptysis. ( Chen, HC; Chen, SC; Huang, MS; Wang, CS; Yang, CJ, 2011) |
"Usually, TXA-associated seizures persist for a few minutes with no progression into status epilepticus." | 6.82 | Tranexamic acid-associated fatal status epilepticus in a paediatric non-cardiac surgery: A case report and literature review. ( Aboul-Fotouh, S; Habib, MZ; Hassan, BEE; Magdy, SM, 2022) |
"Tranexamic acid (TXA) has been used extensively to minimize blood loss in cardiac surgery and more recently in orthopedic surgery." | 5.56 | Tranexamic acid administration during total joint arthroplasty surgery is not associated with an increased risk of perioperative seizures: a national database analysis. ( Fiasconaro, M; Kirksey, MA; Liu, J; Memtsoudis, SG; Poeran, J; Wilson, LA, 2020) |
" Therefore, the dosage of TA should be decreased judiciously in patients with chronic kidney disease especially on hemodialysis to prevent postoperative seizures." | 5.46 | [Two Cases of Convulsive Seizures after Cardiac Surgery Suspiciously Caused by Tranexamic Acid Administration in Patients on Chronic Hemodialysis]. ( Aoi, R; Kawashima, E; Kitagawa, H; Maehira, M; Soga, M; Takahashi, K; Yuasa, M, 2017) |
"Convulsive seizures are a serious postoperative complication after cardiac surgery." | 5.40 | The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. ( Carroll, J; Djaiani, G; Garrido-Olivares, L; Jerath, A; Katznelson, R; Rao, V; Sharma, V; Wasowicz, M, 2014) |
"Convulsive seizures (CS) occur in ∼1% of the patients after cardiac surgery with cardiopulmonary bypass." | 5.39 | Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. ( Börgermann, J; Gillis-Januszewski, T; Koster, A; Lueth, JU; Schirmer, U; Zittermann, A, 2013) |
"Compared to the non-seizure group, seizure patients had an increased rate of postoperative neurological complications, defined as delirium and/or stroke (3." | 5.38 | Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. ( Ariano, RE; Grocott, HP; Jacobsohn, E; Leake, J; Manji, JS; Manji, RA; Menkis, AH, 2012) |
"Postoperative seizures occurred significantly more frequently in TXA patients (7." | 5.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
"All patients with seizures did not have permanent neurological abnormalities." | 5.36 | High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010) |
"The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons." | 5.36 | Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010) |
"However, tAMCA has been shown to cause epileptic seizures." | 5.31 | Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. ( Hopf, R; Redl, H; Schlag, MG; Zifko, U, 2002) |
"Tranexamic acid may cause severe complications when used in the central nervous system." | 5.31 | Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model. ( Hopf, R; Redl, H; Schlag, MG, 2000) |
"An initial retrospective study suggested that tranexamic acid (TXA) administration increased the incidence of seizures in paediatric patients undergoing cardiac surgery." | 5.30 | Safety and efficacy of tranexamic acid in paediatric cardiac surgery: study protocol for a double-blind randomised controlled trial. ( Hu, S; Hua, Z; Jia, Y; Li, S; Liu, J; Ran, J; Shi, J; Wang, R; Wang, X; Wang, Y; Yan, F; Yan, J; Yuan, S; Zhang, Y; Zhang, Z; Zhao, Y; Zheng, Z, 2019) |
"Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes." | 5.24 | Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017) |
"Tranexamic acid (TXA) reduces surgical bleeding and reduces death from bleeding after trauma and childbirth." | 5.12 | Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. ( Murao, S; Nakata, H; Roberts, I; Yamakawa, K, 2021) |
"This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 5.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
"Tranexamic acid (TXA) is one of the measures indicated to reduce bleeding and the need for volume replacement." | 5.12 | Tranexamic acid in Neurosurgery: a controversy indication-review. ( Costa E Silva, LT; da Silva Brito, J; de Faria, JL; de Souza, NB; Figueiredo, EG; Kilesse, CTSM; Pereira, CU; Rabelo, NN, 2021) |
"The aim of this meta-analysis was to assess whether tranexamic acid (TXA) therapy for adult cardiac surgery is associated with an increase in the risk of seizures, and we performed a meta-analysis of randomized controlled trials (RCTs) and non-randomized observational studies." | 4.95 | Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies. ( Ando, T; Takagi, H; Umemoto, T, 2017) |
"To investigate the incidence rate of tranexamic acid (TXA)-associated seizures." | 4.93 | Tranexamic acid-associated seizures: A meta-analysis. ( Lin, Z; Xiaoyi, Z, 2016) |
" The most commonly used antifibrinolytic drug, tranexamic acid, is associated with an increased incidence of postoperative seizures." | 4.93 | Tranexamic acid-associated seizures: Causes and treatment. ( Avramescu, S; Lecker, I; Mazer, CD; Orser, BA; Wang, DS; Whissell, PD, 2016) |
"This study described the outcomes of patients receiving topical, nebulized, endobronchial, or systemic tranexamic acid (TXA) for bleeding events while on extracorporeal membrane oxygenation (ECMO)." | 4.31 | Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation. ( Jakowenko, ND; Kalvelage, EL; Macielak, RJ; Nabzdyk, CGS; Nei, SD; Seelhammer, TG; Wieruszewski, PM, 2023) |
"To evaluate the effects of administering tranexamic acid (TXA) after cardiopulmonary bypass, instead of after anesthesia induction, on postoperative seizures and blood transfusion requirements." | 4.12 | Tranexamic acid after cardiopulmonary bypass does not increase risk of postoperative seizures: a retrospective study. ( Chen, C; Du, L; Liu, J, 2022) |
"This multicenter international experience of pediatric craniofacial surgery reports no increase in seizures or thromboembolic events in those that received antifibrinolytics (tranexamic acid and epsilon-aminocaproic acid) versus those that did not." | 4.12 | Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group. ( Benzon, HA; Goobie, SM; King, MR; Nelson, O; Pérez-Pradilla, C; Staffa, SJ; Stricker, PA, 2022) |
"In cardiac surgery, use of the antifibrinolytic agent tranexamic acid (TXA) and acute perioperative stroke are both associated with convulsive seizures." | 4.02 | Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery. ( Deutsch, MA; Gummert, JF; Hulde, N; Koster, A; von Dossow, V; Zittermann, A, 2021) |
"High-dose tranexamic acid (TXA) can cause seizures in patients who have undergone pulmonary endarterectomy (PTE)." | 3.96 | Deprescribing practices for anticonvulsants after benign seizures secondary to high-dose tranexamic acid in a single, large UK cardiothoracic centre. ( Barrow, L; Jenkins, D; Ng, CY; Tan, Z; Valchanov, K, 2020) |
"The present study aimed to examine the association between tranexamic acid use and adverse effects (seizures, thromboembolism, and renal dysfunction) in a pediatric trauma population using a national inpatient database in Japan." | 3.88 | Safety of Tranexamic Acid During Pediatric Trauma: A Nationwide Database Study. ( Maeda, T; Matsui, H; Michihata, N; Miyata, S; Ohnishi, Y; Sasabuchi, Y; Yasunaga, H, 2018) |
"The incidence of postoperative nonischemic seizures associated with the use of tranexamic acid (TXA) and the possibility of prevention with a low-dose regimen of TXA were evaluated." | 3.85 | Low-Dose Versus High-Dose Tranexamic Acid Reduces the Risk of Nonischemic Seizures After Cardiac Surgery With Cardiopulmonary Bypass. ( Ayoub, C; Chamberland, MÈ; Cogan, J; Couture, P; Denault, A; Deschamps, A; Desjardins, G; Laliberté, É; Lebon, JS; Rochon, A, 2017) |
"The present study aimed to examine the association between tranexamic acid (TXA) use and adverse effects (seizures, thromboembolism, and renal dysfunction) in a pediatric cardiac surgery population using a national inpatient database in Japan." | 3.85 | Safety of Tranexamic Acid in Pediatric Cardiac Surgery: A Nationwide Database Study. ( Maeda, T; Matsui, H; Miyata, S; Ohnishi, Y; Sasabuchi, Y; Yasunaga, H, 2017) |
"Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding." | 3.83 | Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024) |
"A 68-year-old man was admitted and received tranexamic acid for persistent hemoptysis." | 3.77 | Generalized convulsion resulted in hyperammonemia during treatment with tranexamic acid for hemoptysis. ( Chen, HC; Chen, SC; Huang, MS; Wang, CS; Yang, CJ, 2011) |
"To investigate the incidence of postoperative generalized seizures in patients undergoing aortic valve replacement (AVR) under extracorporeal circulation, who received either high-dose tranexamic acid (TXA) or epsilon aminocaproic acid (EACA) as an antifibrinolytic agent." | 3.77 | High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. ( Beyersdorf, F; Keyl, C; Lehane, C; Stampf, S; Trenk, D; Uhl, R; Wiesenack, C, 2011) |
" Postoperatively, a higher incidence of seizures in the first 48 hours was seen with tranexamic acid compared with aprotinin (11% versus 4%, p = 0." | 3.76 | Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients. ( Berman, M; Cardone, D; Dunning, J; Gerrard, C; Jenkins, D; Klein, A; Sharples, L; Tsui, S; Vuylsteke, A, 2010) |
"To compare the efficacy and adverse events of high-dose vs low-dose tranexamic acid in patients undergoing cardiac surgery with cardiopulmonary bypass." | 3.11 | Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. ( Cheng, Z; Feng, W; Liu, S; Pan, W; Shi, J; Sun, H; Wang, W; Wang, Y; Zheng, Z; Zhou, C, 2022) |
"Tranexamic acid (TXA) is an anti-fibrinolytic effective in reducing blood loss in orthopedic surgery." | 3.11 | Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery. ( Clohisy, JCF; Dafrawy, MHE; Frazier, E; Kelly, MP; Lenke, LG; Wolfe, RC, 2022) |
" However, in infants less than 1 year of age, the optimal dosing based on pharmacokinetic (PK) considerations is still under discussion." | 2.84 | Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery. ( Braun, S; Burg, S; Gertler, R; Grassin-Delyle, S; Gruber, M; Martin, K; Tassani-Prell, P; Urien, S; Wiesner, G, 2017) |
"Usually, TXA-associated seizures persist for a few minutes with no progression into status epilepticus." | 2.82 | Tranexamic acid-associated fatal status epilepticus in a paediatric non-cardiac surgery: A case report and literature review. ( Aboul-Fotouh, S; Habib, MZ; Hassan, BEE; Magdy, SM, 2022) |
"All three patients with seizures were ≥65 years old, had "open-chamber" procedures, and had cardiopulmonary bypass times >120 min." | 2.79 | A prospective observational study of seizures after cardiac surgery using continuous EEG monitoring. ( Chase, L; Chu, MW; Fox, SA; Gofton, TE; Murkin, JM; Norton, L; Young, GB, 2014) |
" This meta-analysis aims to provide information on the optimal dosage and delivery method which is effective with the least adverse outcomes." | 2.61 | Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials. ( Gao, X; Guo, J; Hu, W; Ji, H; Lv, H; Ma, Y; Shi, J; Wang, G; Zhang, S, 2019) |
"Tranexamic acid is a well-known antifibrinolytic medication frequently prescribed to individuals with bleeding disorders." | 1.91 | Accidental intrathecal injection of tranexamic acid: a case report. ( Harby, SA; Kohaf, NA, 2023) |
" However, concerns regarding potential adverse reactions, specifically postoperative seizures and thrombotic events, still exist." | 1.72 | Evaluation of the safety of tranexamic acid use in pediatric patients undergoing spinal fusion surgery: a retrospective comparative cohort study. ( Chang, PS; Chatterjee, A; Geiselmann, MT; Ivasyk, I; Jordan, C; Kamel, H; Khormaee, S, 2022) |
"Tranexamic acid (TXA) has been used extensively to minimize blood loss in cardiac surgery and more recently in orthopedic surgery." | 1.56 | Tranexamic acid administration during total joint arthroplasty surgery is not associated with an increased risk of perioperative seizures: a national database analysis. ( Fiasconaro, M; Kirksey, MA; Liu, J; Memtsoudis, SG; Poeran, J; Wilson, LA, 2020) |
"Tranexamic acid (TXA) is a common antifibrinolytic agent used to minimize bleeding in cardiac surgery." | 1.48 | Tranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen. ( Beattie, WS; Bojko, B; Jerath, A; Looby, N; Pang, KS; Pawliszyn, J; Reyes-Garces, N; Vasiljevic, T; Wąsowicz, M; Wijeysundera, D; Yang, QJ; Yau, TM, 2018) |
" Therefore, the dosage of TA should be decreased judiciously in patients with chronic kidney disease especially on hemodialysis to prevent postoperative seizures." | 1.46 | [Two Cases of Convulsive Seizures after Cardiac Surgery Suspiciously Caused by Tranexamic Acid Administration in Patients on Chronic Hemodialysis]. ( Aoi, R; Kawashima, E; Kitagawa, H; Maehira, M; Soga, M; Takahashi, K; Yuasa, M, 2017) |
"Tranexamic acid was introduced during these procedures in 2006." | 1.43 | Use of Tranexamic Acid Is Associated with Reduced Blood Product Transfusion in Complex Skull Base Neurosurgical Procedures: A Retrospective Cohort Study. ( Akagami, R; Flexman, AM; Mebel, D, 2016) |
"She had no further episodes of convulsion till dis-charge and during the two months of follow-up." | 1.40 | Tranexamic acid overdosage-induced generalized seizure in renal failure. ( Agarwal, SK; Bhat, A; Bhowmik, DM; Dogra, M; Vibha, D, 2014) |
"Convulsive seizures are a serious postoperative complication after cardiac surgery." | 1.40 | The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. ( Carroll, J; Djaiani, G; Garrido-Olivares, L; Jerath, A; Katznelson, R; Rao, V; Sharma, V; Wasowicz, M, 2014) |
"The seizures were likely due to a total dose of 8 g of tranexamic acid (TXA) administered intraoperatively." | 1.39 | [A case of postoperative convulsive seizure following tranexamic acid infusion during aortic valve replacement]. ( Ichikawa, J; Kodaka, M; Komori, M; Kubota, S; Nakano, K; Nishiyama, K; Sato, N, 2013) |
"Convulsive seizures (CS) occur in ∼1% of the patients after cardiac surgery with cardiopulmonary bypass." | 1.39 | Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. ( Börgermann, J; Gillis-Januszewski, T; Koster, A; Lueth, JU; Schirmer, U; Zittermann, A, 2013) |
" Future tranexamic acid trials should assess the blood-conserving effect of tranexamic acid at a lower dosage and specifically monitor for seizure occurrence." | 1.38 | High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. ( Dagenais, F; Dionne, S; Kalavrouziotis, D; Mohammadi, S; Voisine, P, 2012) |
"Compared to the non-seizure group, seizure patients had an increased rate of postoperative neurological complications, defined as delirium and/or stroke (3." | 1.38 | Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. ( Ariano, RE; Grocott, HP; Jacobsohn, E; Leake, J; Manji, JS; Manji, RA; Menkis, AH, 2012) |
"Although the fourfold risk for seizures using TXA was not significant, we currently use EACA in paediatric cardiac surgery." | 1.37 | Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery. ( Breuer, T; Gertler, R; Hapfelmeier, A; Hess, J; Lange, R; Martin, K; Schreiber, C; Wiesner, G, 2011) |
"Postoperative seizures occurred significantly more frequently in TXA patients (7." | 1.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
"All patients with seizures did not have permanent neurological abnormalities." | 1.36 | High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010) |
"The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons." | 1.36 | Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010) |
"Ten hours later, the patient developed myoclonus of his upper extremities and face." | 1.35 | Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia. ( Arami, A; Jafari, A; Mohseni, K; Nobahar, MR, 2009) |
"Tranexamic acid may cause severe complications when used in the central nervous system." | 1.31 | Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model. ( Hopf, R; Redl, H; Schlag, MG, 2000) |
"However, tAMCA has been shown to cause epileptic seizures." | 1.31 | Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. ( Hopf, R; Redl, H; Schlag, MG; Zifko, U, 2002) |
Research
Studies (74)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (2.70) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (9.46) | 29.6817 |
2010's | 47 (63.51) | 24.3611 |
2020's | 18 (24.32) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, C | 1 |
Liu, J | 3 |
Du, L | 1 |
Murao, S | 1 |
Nakata, H | 1 |
Roberts, I | 1 |
Yamakawa, K | 1 |
Aboul-Fotouh, S | 1 |
Habib, MZ | 1 |
Magdy, SM | 1 |
Hassan, BEE | 1 |
Clohisy, JCF | 1 |
Lenke, LG | 1 |
Dafrawy, MHE | 1 |
Wolfe, RC | 1 |
Frazier, E | 1 |
Kelly, MP | 1 |
Ivasyk, I | 1 |
Chatterjee, A | 1 |
Jordan, C | 1 |
Geiselmann, MT | 1 |
Chang, PS | 1 |
Kamel, H | 1 |
Khormaee, S | 1 |
Shi, J | 3 |
Zhou, C | 1 |
Pan, W | 1 |
Sun, H | 1 |
Liu, S | 1 |
Feng, W | 1 |
Wang, W | 1 |
Cheng, Z | 1 |
Wang, Y | 2 |
Zheng, Z | 2 |
King, MR | 1 |
Staffa, SJ | 1 |
Stricker, PA | 1 |
Pérez-Pradilla, C | 1 |
Nelson, O | 1 |
Benzon, HA | 1 |
Goobie, SM | 1 |
Patel, S | 1 |
Harby, SA | 1 |
Kohaf, NA | 1 |
Li, S | 2 |
Liu, M | 1 |
Yang, J | 1 |
Yan, X | 1 |
Wu, Y | 1 |
Zhang, L | 1 |
Zeng, M | 1 |
Zhou, D | 1 |
Peng, Y | 1 |
Sessler, DI | 1 |
Jakowenko, ND | 1 |
Seelhammer, TG | 1 |
Nabzdyk, CGS | 1 |
Macielak, RJ | 1 |
Nei, SD | 1 |
Kalvelage, EL | 1 |
Wieruszewski, PM | 1 |
Hulde, N | 3 |
Zittermann, A | 6 |
Deutsch, MA | 3 |
von Dossow, V | 3 |
Gummert, JF | 3 |
Koster, A | 6 |
Zhang, Y | 1 |
Jia, Y | 1 |
Yuan, S | 1 |
Wang, R | 1 |
Zhang, Z | 1 |
Wang, X | 1 |
Ran, J | 1 |
Zhao, Y | 1 |
Hua, Z | 1 |
Yan, J | 1 |
Hu, S | 1 |
Yan, F | 1 |
Aflaki, K | 1 |
Bhuptani, P | 1 |
Aflaki, S | 1 |
Kirksey, MA | 1 |
Wilson, LA | 1 |
Fiasconaro, M | 1 |
Poeran, J | 1 |
Memtsoudis, SG | 1 |
de Faria, JL | 1 |
da Silva Brito, J | 1 |
Costa E Silva, LT | 1 |
Kilesse, CTSM | 1 |
de Souza, NB | 1 |
Pereira, CU | 1 |
Figueiredo, EG | 1 |
Rabelo, NN | 1 |
Tan, Z | 1 |
Ng, CY | 1 |
Jenkins, D | 2 |
Barrow, L | 1 |
Valchanov, K | 1 |
Shrestha, IK | 1 |
Ruan, TY | 1 |
Lin, L | 1 |
Tan, M | 1 |
Na, XQ | 1 |
Qu, QC | 1 |
Chen, JC | 1 |
Si, YY | 1 |
Tao, JP | 1 |
Couture, P | 1 |
Lebon, JS | 1 |
Laliberté, É | 1 |
Desjardins, G | 1 |
Chamberland, MÈ | 1 |
Ayoub, C | 1 |
Rochon, A | 1 |
Cogan, J | 1 |
Denault, A | 1 |
Deschamps, A | 1 |
Gerstein, NS | 1 |
Deriy, L | 1 |
Patel, PA | 1 |
Jerath, A | 2 |
Yang, QJ | 1 |
Pang, KS | 1 |
Looby, N | 1 |
Reyes-Garces, N | 1 |
Vasiljevic, T | 1 |
Bojko, B | 1 |
Pawliszyn, J | 1 |
Wijeysundera, D | 1 |
Beattie, WS | 1 |
Yau, TM | 1 |
Wąsowicz, M | 2 |
Maeda, T | 2 |
Michihata, N | 1 |
Sasabuchi, Y | 2 |
Matsui, H | 2 |
Ohnishi, Y | 2 |
Miyata, S | 2 |
Yasunaga, H | 2 |
Kawashima, E | 1 |
Yuasa, M | 1 |
Maehira, M | 1 |
Soga, M | 1 |
Aoi, R | 1 |
Takahashi, K | 1 |
Kitagawa, H | 1 |
Loi, MM | 1 |
Derderian, SC | 1 |
Bennett, TD | 1 |
Guo, J | 1 |
Gao, X | 1 |
Ma, Y | 1 |
Lv, H | 1 |
Hu, W | 1 |
Zhang, S | 1 |
Ji, H | 1 |
Wang, G | 1 |
Merriman, B | 1 |
Mayson, K | 1 |
Sawka, A | 1 |
Akagami, R | 2 |
Flexman, AM | 2 |
Ichikawa, J | 1 |
Kodaka, M | 1 |
Nishiyama, K | 1 |
Sato, N | 1 |
Kubota, S | 1 |
Nakano, K | 1 |
Komori, M | 1 |
Alston, RP | 1 |
McMullan, V | 1 |
Schirmer, U | 3 |
Kratzer, S | 1 |
Irl, H | 1 |
Mattusch, C | 1 |
Bürge, M | 1 |
Kurz, J | 1 |
Kochs, E | 1 |
Eder, M | 1 |
Rammes, G | 1 |
Haseneder, R | 1 |
Bhat, A | 1 |
Bhowmik, DM | 1 |
Vibha, D | 1 |
Dogra, M | 1 |
Agarwal, SK | 1 |
Sharma, V | 1 |
Katznelson, R | 1 |
Garrido-Olivares, L | 1 |
Carroll, J | 1 |
Rao, V | 1 |
Djaiani, G | 1 |
Gofton, TE | 1 |
Chu, MW | 1 |
Norton, L | 1 |
Fox, SA | 1 |
Chase, L | 1 |
Murkin, JM | 2 |
Young, GB | 1 |
Gertler, R | 4 |
Wiesner, G | 5 |
Tassani-Prell, P | 2 |
Martin, K | 5 |
Gruber, M | 2 |
Mebel, D | 1 |
Lecker, I | 3 |
Wang, DS | 2 |
Whissell, PD | 1 |
Avramescu, S | 1 |
Mazer, CD | 3 |
Orser, BA | 3 |
Idialisoa, R | 1 |
Jouffroy, R | 1 |
Philippe, P | 1 |
Lamhaut, L | 1 |
Baud, F | 1 |
Carli, P | 1 |
Vivien, B | 1 |
Lin, Z | 1 |
Xiaoyi, Z | 1 |
Myles, PS | 1 |
Smith, JA | 1 |
Forbes, A | 1 |
Silbert, B | 1 |
Jayarajah, M | 1 |
Painter, T | 1 |
Cooper, DJ | 1 |
Marasco, S | 2 |
McNeil, J | 1 |
Bussières, JS | 1 |
McGuinness, S | 1 |
Byrne, K | 1 |
Chan, MT | 1 |
Landoni, G | 1 |
Wallace, S | 1 |
Grassin-Delyle, S | 1 |
Urien, S | 1 |
Braun, S | 1 |
Burg, S | 1 |
Takagi, H | 1 |
Ando, T | 1 |
Umemoto, T | 1 |
Breuer, T | 3 |
Lange, R | 3 |
Tassani, P | 2 |
Mohseni, K | 1 |
Jafari, A | 1 |
Nobahar, MR | 1 |
Arami, A | 1 |
Wang, CS | 1 |
Yang, CJ | 1 |
Chen, SC | 1 |
Chen, HC | 1 |
Huang, MS | 1 |
Falter, F | 1 |
Granton, J | 1 |
Young, B | 1 |
Burt, C | 1 |
Chu, M | 1 |
Fox, MA | 1 |
Bell, D | 1 |
Almeida, A | 1 |
Rowland, M | 1 |
Casati, V | 1 |
Romano, A | 1 |
Novelli, E | 1 |
D'Angelo, A | 1 |
Berman, M | 1 |
Cardone, D | 1 |
Sharples, L | 1 |
Vuylsteke, A | 1 |
Klein, A | 1 |
Gerrard, C | 1 |
Dunning, J | 1 |
Tsui, S | 1 |
Hapfelmeier, A | 1 |
Schreiber, C | 1 |
Hess, J | 1 |
Knorr, J | 1 |
Macguill, M | 1 |
Keyl, C | 1 |
Uhl, R | 1 |
Beyersdorf, F | 1 |
Stampf, S | 1 |
Lehane, C | 1 |
Wiesenack, C | 1 |
Trenk, D | 1 |
Goldstone, AB | 1 |
Bronster, DJ | 1 |
Chikwe, J | 1 |
Kalavrouziotis, D | 1 |
Voisine, P | 1 |
Mohammadi, S | 1 |
Dionne, S | 1 |
Dagenais, F | 1 |
Manji, RA | 1 |
Grocott, HP | 1 |
Leake, J | 1 |
Ariano, RE | 1 |
Manji, JS | 1 |
Menkis, AH | 1 |
Jacobsohn, E | 1 |
Ferraris, VA | 1 |
Akay, MH | 1 |
Senay, S | 1 |
Karabulut, H | 1 |
Toraman, F | 1 |
Kocyiğit, M | 1 |
Alhan, HC | 1 |
Börgermann, J | 1 |
Lueth, JU | 1 |
Gillis-Januszewski, T | 1 |
Romaschin, AD | 1 |
Peterson, M | 1 |
Schwinn, DA | 1 |
Mackensen, GB | 1 |
Brown, EN | 1 |
Pusateri, AE | 1 |
Weiskopf, RB | 1 |
Bebarta, V | 1 |
Butler, F | 1 |
Cestero, RF | 1 |
Chaudry, IH | 1 |
Deal, V | 1 |
Dorlac, WC | 1 |
Gerhardt, RT | 1 |
Given, MB | 1 |
Hansen, DR | 1 |
Hoots, WK | 1 |
Klein, HG | 1 |
Macdonald, VW | 1 |
Mattox, KL | 1 |
Michael, RA | 1 |
Mogford, J | 1 |
Montcalm-Smith, EA | 1 |
Niemeyer, DM | 1 |
Prusaczyk, WK | 1 |
Rappold, JF | 1 |
Rassmussen, T | 1 |
Rentas, F | 1 |
Ross, J | 1 |
Thompson, C | 1 |
Tucker, LD | 1 |
Dehghani, E | 1 |
Trenfield, S | 1 |
Yeh, HM | 1 |
Lau, HP | 1 |
Lin, PL | 1 |
Sun, WZ | 1 |
Mok, MS | 1 |
Yamaura, A | 1 |
Nakamura, T | 1 |
Makino, H | 1 |
Hagihara, Y | 1 |
Pellegrini, A | 1 |
Giaretta, D | 1 |
Chemello, R | 1 |
Zanotto, L | 1 |
Testa, G | 1 |
Schlag, MG | 3 |
Hopf, R | 3 |
Redl, H | 3 |
Fodstad, H | 1 |
Zifko, U | 1 |
Furtmüller, R | 1 |
Berger, M | 1 |
Huck, S | 1 |
Sieghart, W | 1 |
Clinical Trials (13)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial[NCT02053363] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
Pharmacokinetics of Tranexamic Acid in Patients With Varying Renal Function Undergoing Cardiac Surgery With the Use of Cardiopulmonary Bypass[NCT01609686] | 49 participants (Actual) | Observational | 2012-01-31 | Completed | |||
The Effect of Two Different Tranexamic Acid Dose Regimens on Intraoperative and Postoperative Bleeding in Coronary Artery Bypass Surgery[NCT05994989] | 60 participants (Anticipated) | Observational | 2023-08-14 | Recruiting | |||
Seizures After Cardiac Surgery -- A Prospective Study With Continuous EEG Monitoring[NCT01291992] | 100 participants (Actual) | Observational | 2010-09-30 | Completed | |||
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial[NCT04863339] | Phase 2 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to Challenges in recruitment) | ||
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery[NCT01980355] | 76 participants (Actual) | Interventional | 2012-06-12 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Blood Loss
"To compare the estimated blood loss in patients undergoing complex, reconstructive, spinal fusion surgeries receiving one of two dosing protocols for the anti-fibrinolytic, TXA.~Estimated blood loss was calculated by suction canister volume minus intraoperative irrigation fluid plus blood content in sponges as estimated by weight for all cases." (NCT02053363)
Timeframe: This outcome is measured during surgery, from exposure to wound closure, approximately 8 hours.
Intervention | mL (Mean) |
---|---|
High Dose/Study Group | 2046 |
Standard of Care/Control | 1596 |
Number of Patients Sustaining Intraoperative or 90 Day Complications
To compare the rates of intraoperative complications and 90 day complications observed in the two groups. (NCT02053363)
Timeframe: Perioperative complications were defined as complications occurring within 90 days of surgery.
Intervention | Participants (Count of Participants) |
---|---|
High Dose/Study Group | 2 |
Standard of Care/Control | 3 |
Red Blood Cell Transfusions
To compare the mean volume (mL) of packed red blood cell (PRBC) transfusions given to the two groups. Volumes of RBC vary from bag to bag and real volumes will be recorded as provided by the blood bank. (NCT02053363)
Timeframe: Participants will be followed for the duration of their hospital stay measured from day of surgery to day of discharge from the hospital, approximately 7 days.
Intervention | mL (Mean) |
---|---|
High Dose/Study Group | 1259 |
Standard of Care/Control | 935 |
Change in Hemoglobin
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
Intervention | grams per deciliter (Mean) |
---|---|
Tranexamic Acid | -1.8 |
Placebo | -1.9 |
Length of Stay
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
Intervention | days (Median) |
---|---|
Tranexamic Acid | 3 |
Placebo | 3 |
Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours
(NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 35 |
Placebo | 32 |
Number of Participants Who Received Open Label TXA or Other Antifibrinolytic
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 108 |
Placebo | 109 |
Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 233 |
Placebo | 231 |
Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 892 |
Placebo | 986 |
Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 20 |
Placebo | 19 |
Number of Participants Who Were Transfused With Other Blood Products
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 29 |
Placebo | 31 |
Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 649 |
Placebo | 732 |
Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 12 |
Placebo | 13 |
Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 339 |
Placebo | 368 |
Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 201 |
Placebo | 233 |
Number of Participants With Postpartum Infectious Complications
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 162 |
Placebo | 125 |
Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 2 |
Placebo | 0 |
Mean Concentration of TxA in Plasma Collected From Participants
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
Intervention | microgram per milliliter per kilogram (Mean) |
---|---|
Topical TxA (Intervention) | 0.58 |
Intravenous TxA (Control) | 1.10 |
Median Number of Hours Participants Spent in ICU
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
Intervention | hours (Median) |
---|---|
Topical TxA (Intervention) | 23 |
Intravenous TxA (Control) | 26 |
Median Volume of Mediastinal Fluid Collected From Participants
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
Intervention | mL (Median) |
---|---|
Topical TxA (Intervention) | 500 |
Intravenous TxA (Control) | 540 |
Number of Participants With Mortality
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 1 |
Intravenous TxA (Control) | 1 |
Number of Participants With RBC Transfusion
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 19 |
Intravenous TxA (Control) | 23 |
Number of Participants With Re-operation for Bleeding or Tamponade
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 0 |
Intravenous TxA (Control) | 1 |
Number of Participants With Seizures
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Topical TxA (Intervention) | 0 |
Intravenous TxA (Control) | 1 |
Estimated Blood Loss
Surgical blood loss estimation (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
Intervention | mL (Median) |
---|---|
Tranexamic Acid | 450 |
Placebo | 365 |
Number of Participants Who Required Transfusion
To determine the impact of perioperative administration of tranexamic acid on blood loss and transfusion rates in major oncologic surgery (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 8 |
Placebo | 5 |
Reviews
9 reviews available for tranexamic acid and Absence Seizure
Article | Year |
---|---|
Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Antifibrinolytic Agents; Hemorrhage; Humans; Risk Assessment; Seizures; Str | 2021 |
Tranexamic acid-associated fatal status epilepticus in a paediatric non-cardiac surgery: A case report and literature review.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Humans; Male; Propofol; Seiz | 2022 |
Tranexamic acid in Neurosurgery: a controversy indication-review.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Brain Injuries, Traumatic; | 2021 |
The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis.
Topics: Adolescent; Blood Loss, Surgical; Female; Humans; Infusions, Intravenous; Intraoperative Complicatio | 2021 |
Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials.
Topics: Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical Procedures; Dose-Response Relationship, | 2019 |
Tranexamic acid-associated seizures: Causes and treatment.
Topics: Animals; Antifibrinolytic Agents; Humans; Seizures; Tranexamic Acid | 2016 |
Tranexamic acid-associated seizures: A meta-analysis.
Topics: Antifibrinolytic Agents; Databases, Bibliographic; Dose-Response Relationship, Drug; Humans; Odds Ra | 2016 |
Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac S | 2017 |
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Postoperative Complications; Randomized Controlled Tria | 2013 |
Trials
7 trials available for tranexamic acid and Absence Seizure
Article | Year |
---|---|
Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Prospective Studies; Seizures; Tranexa | 2022 |
Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial.
Topics: Adult; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Dose-Response R | 2022 |
Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Meningeal Neoplasms; Men | 2024 |
Safety and efficacy of tranexamic acid in paediatric cardiac surgery: study protocol for a double-blind randomised controlled trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Cardi | 2019 |
A prospective observational study of seizures after cardiac surgery using continuous EEG monitoring.
Topics: Aged; Antifibrinolytic Agents; Cardiac Surgical Procedures; Electroencephalography; Female; Follow-U | 2014 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedu | 2017 |
Other Studies
58 other studies available for tranexamic acid and Absence Seizure
Article | Year |
---|---|
Tranexamic acid after cardiopulmonary bypass does not increase risk of postoperative seizures: a retrospective study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiopulmonary Bypass; Humans; Retrospective | 2022 |
Evaluation of the safety of tranexamic acid use in pediatric patients undergoing spinal fusion surgery: a retrospective comparative cohort study.
Topics: Adolescent; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Cohort Studies; Humans; Pulmonary | 2022 |
Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Craniosynostoses; Humans; I | 2022 |
Tranexamic acid-associated seizures in a paediatric patient.
Topics: Anticonvulsants; Child; Humans; Propofol; Seizures; Status Epilepticus; Tranexamic Acid | 2022 |
Accidental intrathecal injection of tranexamic acid: a case report.
Topics: Adult; Atracurium; Humans; Injections, Spinal; Male; Saline Solution; Seizures; Thiopental; Tranexam | 2023 |
Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation.
Topics: Adolescent; Adult; Extracorporeal Membrane Oxygenation; Hemorrhage; Hemostatics; Humans; Retrospecti | 2023 |
Tranexamic acid and convulsive seizures after off-pump coronary artery bypass surgery: the role of renal insufficiency.
Topics: Adult; Aged; Antifibrinolytic Agents; Coronary Artery Bypass, Off-Pump; Female; Glomerular Filtratio | 2019 |
Phenytoin Pharmacokinetics and Cardiopulmonary Bypass: A Case of Seizures in the Postoperative Period.
Topics: Cardiopulmonary Bypass; Humans; Phenytoin; Postoperative Period; Seizures; Tranexamic Acid | 2020 |
Tranexamic acid and convulsive seizures after isolated coronary artery bypass surgery: the role of cardiopulmonary bypass and renal function.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Glomerular Fi | 2020 |
Tranexamic acid administration during total joint arthroplasty surgery is not associated with an increased risk of perioperative seizures: a national database analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Seizures; Tra | 2020 |
Deprescribing practices for anticonvulsants after benign seizures secondary to high-dose tranexamic acid in a single, large UK cardiothoracic centre.
Topics: Anticonvulsants; Antifibrinolytic Agents; Deprescriptions; Dose-Response Relationship, Drug; Endarte | 2020 |
Associations of preoperative stroke and tranexamic acid administration with convulsive seizures in valvular open-heart surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Humans; Retrospective St | 2021 |
Low-Dose Versus High-Dose Tranexamic Acid Reduces the Risk of Nonischemic Seizures After Cardiac Surgery With Cardiopulmonary Bypass.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypas | 2017 |
Tranexamic Acid Use in Cardiac Surgery: Hemostasis, Seizures, or a Little of Both.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Hemostasis; Humans; Seiz | 2018 |
Tranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen.
Topics: Aged; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Drug Administrat | 2018 |
Safety of Tranexamic Acid During Pediatric Trauma: A Nationwide Database Study.
Topics: Acute Kidney Injury; Antifibrinolytic Agents; Case-Control Studies; Child; Child, Preschool; Databas | 2018 |
[Two Cases of Convulsive Seizures after Cardiac Surgery Suspiciously Caused by Tranexamic Acid Administration in Patients on Chronic Hemodialysis].
Topics: Aged; Antifibrinolytic Agents; Aortic Valve; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Hu | 2017 |
Tranexamic Acid and Seizures in Pediatric Trauma.
Topics: Child; Humans; Seizures; Tranexamic Acid | 2018 |
Postoperative seizure in a neurosurgical patient: Should tranexamic acid be on the differential?
Topics: Cardiac Surgical Procedures; Female; Humans; Male; Postoperative Complications; Seizures; Tranexamic | 2013 |
[A case of postoperative convulsive seizure following tranexamic acid infusion during aortic valve replacement].
Topics: Aged, 80 and over; Aortic Valve; Humans; Male; Postoperative Complications; Seizures; Tranexamic Aci | 2013 |
Observational studies are not reliable enough when making decisions about individual patient care.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Female; Humans; Male; | 2013 |
Safety of antifibrinolytic therapy during cardiac surgery and randomized controlled trials.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Female; Humans; Male; | 2013 |
Tranexamic acid impairs γ-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures?
Topics: Amygdala; Animals; Antifibrinolytic Agents; Disease Models, Animal; Electric Stimulation; Male; Mice | 2014 |
Tranexamic acid overdosage-induced generalized seizure in renal failure.
Topics: Anticonvulsants; Antifibrinolytic Agents; Drug Overdose; Female; Humans; Kidney; Menorrhagia; Middle | 2014 |
The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypas | 2014 |
Measurement of tranexamic acid serum concentrations in a 7-month-old infant with clinical seizures after open heart surgery.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Humans; Infant; Postoperative Complications; S | 2014 |
Use of Tranexamic Acid Is Associated with Reduced Blood Product Transfusion in Complex Skull Base Neurosurgical Procedures: A Retrospective Cohort Study.
Topics: Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Erythrocyte Transfusion; Female; Hemoglo | 2016 |
Beware of using tranexamic acid in parturients with eclampsia.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cesarean Section; Critical Care; Eclampsia; Fe | 2016 |
Safety of Tranexamic Acid in Pediatric Cardiac Surgery: A Nationwide Database Study.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Child, Preschool; Cohort Studies; Databases, F | 2017 |
The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Coronary Artery Bypass | 2008 |
Polymyoclonus seizure resulting from accidental injection of tranexamic acid in spinal anesthesia.
Topics: Anesthesia, General; Anesthesia, Spinal; Anticonvulsants; Antifibrinolytic Agents; Critical Care; Hu | 2009 |
Generalized convulsion resulted in hyperammonemia during treatment with tranexamic acid for hemoptysis.
Topics: Aged; Antifibrinolytic Agents; Hemoptysis; Humans; Hyperammonemia; Male; Seizures; Tranexamic Acid | 2011 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
Tranexamic acid: how much is enough?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Dose-Response Relationsh | 2010 |
Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cohort Studies; Coron | 2010 |
Tranexamic acid for trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Nervous System Diseases; Randomized Controlled Trials a | 2010 |
Safety and efficacy of aprotinin and tranexamic acid in pulmonary endarterectomy surgery with hypothermia: review of 200 patients.
Topics: Adult; Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Endarterectomy; Female; Hemos | 2010 |
Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical Procedures; Cardiopu | 2011 |
Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.
Topics: Aged; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical | 2011 |
High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aminocaproic Acid; Antifibrinolytic Agents; Aortic Valve; Drug Administrati | 2011 |
Seizures after adult cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Female; Humans; Male; Posto | 2011 |
"Seizing" the opportunity to understand antifibrinolytic drugs.
Topics: Cardiac Surgical Procedures; Female; Humans; Male; Postoperative Complications; Seizures; Tranexamic | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antifibrinolytic Agents; Cardiac Surgical Procedures; Coho | 2012 |
Invited commentary.
Topics: Cardiopulmonary Bypass; Female; Heart Diseases; Humans; Male; Seizures; Tranexamic Acid | 2012 |
Low-dose tranexamic acid use in isolated coronary artery bypass surgery.
Topics: Cardiopulmonary Bypass; Female; Heart Diseases; Humans; Male; Seizures; Tranexamic Acid | 2012 |
Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia; Antifibrinolytic Agents; Cardiac Surgical Pr | 2013 |
Tranexamic acid concentrations associated with human seizures inhibit glycine receptors.
Topics: Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Animals; Anticonvulsants; Aprotinin; Binding, Com | 2012 |
Understanding the TXA seizure connection.
Topics: Animals; GABA-A Receptor Antagonists; Humans; Receptors, Glycine; Seizures; Tranexamic Acid | 2012 |
Tranexamic acid in open cardiac surgery with cardiopulmonary bypass, convulsive seizures, and in-hospital mortality.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Female; Humans; Male; | 2013 |
Reply from the authors.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Female; Humans; Male; | 2013 |
Convulsions and refractory ventricular fibrillation after intrathecal injection of a massive dose of tranexamic acid.
Topics: Adenocarcinoma; Aged; Antifibrinolytic Agents; Cardiopulmonary Resuscitation; Drug Overdose; Fatal O | 2003 |
Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Blood Pressure; Cerebral Cortex; Cisterna Magna; Cyclohe | 1980 |
Feline generalized epilepsy induced by tranexamic acid (AMCA).
Topics: Administration, Topical; Animals; Cats; Cerebral Cortex; Cyclohexanecarboxylic Acids; Dose-Response | 1982 |
Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model.
Topics: Animals; Antifibrinolytic Agents; Aprotinin; Drug Combinations; Fibrin Tissue Adhesive; Gait; Male; | 2000 |
Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model.
Topics: Animals; Antifibrinolytic Agents; Fibrin Tissue Adhesive; Humans; Rats; Seizures; Subdural Space; Ti | 2001 |
Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.
Topics: Animals; Antifibrinolytic Agents; Cerebral Cortex; Electroencephalography; Fibrin Tissue Adhesive; M | 2002 |
Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect.
Topics: Animals; Antifibrinolytic Agents; Binding, Competitive; Brain Chemistry; Cell Line; Dizocilpine Male | 2002 |